Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety, Tolerability, and Effectiveness of CTH120 in Adult Males With Fragile X Syndrome

NCT07654114 is registered in ClinicalTrials.gov with Connecta Therapeutics, S.L. as lead sponsor.

NCT NCT07654114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07654114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety, Tolerability, and Effectiveness of CTH120 in Adult Males With Fragile X Syndrome
Lead sponsor
Connecta Therapeutics, S.L.
Phase
Phase 2
Overall status
Recruiting
Start date
May 21, 2026
Completion date
May 31, 2027
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

fragile x syndrome, fragile x syndrome (fxs)